Abhinav Drug Chem Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
as on 16-12-2024
- Paid Up Capital ₹ 1.00 Cr
as on 16-12-2024
- Company Age 34 Year, 1 Month
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 10.40 Cr
as on 16-12-2024
- Revenue -91.77%
(FY 2021)
- Profit 5.31%
(FY 2021)
- Ebitda -109.12%
(FY 2021)
- Net Worth -1.92%
(FY 2021)
- Total Assets -1.24%
(FY 2021)
About Abhinav Drug Chem
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 1.00 Cr.
The company currently has active open charges totaling ₹10.40 Cr.
Vikram Kothari and Chetna Kothari serve as directors at the Company.
- CIN/LLPIN
U24232GJ1990PTC014646
- Company No.
014646
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
15 Nov 1990
- Date of AGM
30 Jun 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Bhavnagar, Gujarat, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Abhinav Drug Chem?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Vikram Kothari  | Managing Director | 30-Sep-2005 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Chetna Kothari | Whole-Time Director | 30-Sep-2005 | Current |
Financial Performance of Abhinav Drug Chem.
Abhinav Drug Chem Private Limited, for the financial year ended 2021, experienced significant reduction in revenue, with a 91.77% decrease. The company also saw a slight improvement in profitability, with a 5.31% increase in profit. The company's net worth dipped by a decrease of 1.92%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Abhinav Drug Chem?
In 2020, Abhinav Drug Chem had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Anan Drug And Chem LimitedActive 33 years 6 monthsVikram Kothari and Chetna Kothari are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 02 Nov 2017 | ₹7.75 Cr | Open |
Oriental Bank Of Commerce Creation Date: 26 Apr 2010 | ₹5.25 M | Open |
Oriental Bank Of Commerce Creation Date: 13 Jul 2006 | ₹2.13 Cr | Open |
How Many Employees Work at Abhinav Drug Chem?
Unlock and access historical data on people associated with Abhinav Drug Chem, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Abhinav Drug Chem, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Abhinav Drug Chem's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
